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ABSTRACT The effect of administration of SM 21 on memory processes was evaluated in the mouse
passive avoidance and in the rat social learning tests. SM 21 (10–20 mg kg–1 i.p.) prevented amnesia in-
duced by scopolamine and dicyclomine as tested by the mouse passive avoidance test and prevented
memory disruption by AF-64A and benehexol ascertained by the rat passive avoidance test. Both SM 21
enantiomers were able to abolish dicyclomine-induced amnesia in mice. SM 21, starting from the dose of
10 mg kg–1 i.p., antagonized the memory impairment produced by mecamylamine, baclofen, and diphen-
hydramine in mice, as well as amnesia induced by diazepam in rats. SM 21, at doses ranging between 10
and 30 mg kg–1 i.p., prevented memory reduction in mice by hypoxia in the passive avoidance test. In the
social learning test, SM 21 (10 mg kg–1 i.p.) injected in adult rats reduced the duration of active exploration
of a familiar partner in the second session of the test. SM 21 prevented amnesia in both mice and rats
comparable to that of the cholinesterase inhibitor physostigmine (0.2 mg kg–1 i.p.), the M1 selective agonist
AF-102B (10 mg kg–1 i.p.), and the nootropic drug piracetam (30 mg kg–1 i.p.). These results demonstrated
the ability of SM 21 to modulate memory functions and suggests that SM 21 could be useful in the treat-
ment of cognitive deficits. Drug Dev. Res. 47:118–126, 1999. © 1999 Wiley-Liss, Inc.
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INTRODUCTION
Cholinergic activity has long been associated with
memory processes. Morphological and neurochemical
studies of Alzheimer’s disease, the major type of demen-
tia, have revealed marked decreases in the cholinergic
innervation of the cortex and hippocampus [Bartus et al.,
1982; Mash et al., 1985; Whitehouse, 1986]. Drugs in-
volving cholinergic stimulation alleviate cognitive dys-
functions in Alzheimer’s disease [Bartus et al., 1982] and,
in particular, M1-selective agonists have been proposed
as a promising treatment strategy in this pathology [Mash
et al., 1985; Whitehouse, 1986; Fisher et al., 1989;
Gualtieri et al., 1995]. On the other hand, cholinergic
blockade produces significant impairments of cognitive
functions. A delay-dependent disruption following treat-
ment with scopolamine and atropine, which appeared to
resemble that occurring spontaneously in aged subjects
and in Alzheimer patients, has been reported [Deutsch,
1971; Bartus and Johnson, 1976]. Ghelardini et al. [1997b]
reported that the antimuscarinic compound atropine, at
very low doses, was able to prevent amnesia in mice and
in particular this beneficial effect was attributable to the
R-(+)-enantiomer of atropine, R-(+)-hyoscyamine, since
S-(–)-hyoscyamine was ineffective. It is interesting to note
that this antiamnesiac activity, different from that pro-
duced by direct muscarinic agonists and cholinesterase
inhibitors, was not accompanied by typical cholinergic
symptomatology, such as tremors, lacrimation, sialorrhea,
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diarrhea etc., Bartolini et al. [1994], investigating the
paradoxical effect of atropine, using microdialysis tech-
niques demonstrated that R-(+)-hyoscyamine, at
antiamnesic doses, produced an increase in acetylcho-
line (ACh) release from the rat cerebral cortex in vivo.
On these bases, a synthetic program to modify the chemi-
cal structure of atropine was started, aimed at develop-
ing cholinergic amplifiers as endowed with ameliorated
antiamnesic activity as atropine, but lacking the cholin-
ergic side effects of atropine. These compounds would,
therefore, be potentially useful in pathological conditions
such as Alzheimer’s disease, that are characterized by
cholinergic deficit. Of the many compounds synthesized
and studied, the racemate [Gualtieri et al., 1994] and the
enantiomers [Romanelli et al., 1996] of the compound
labeled SM 21 (3-α-tropanyl 2-[4-(Cl-phenoxy)] buta-
noate) showed the best pharmacological profile.
SM 21 antiamnesic properties were investigated in
mice and rats using the passive avoidance and social learn-
ing tests, whereas the incidence of behavioral side ef-
fects was detected by the rota-rod test and Animex
apparatus.
MATERIALS AND METHODS
Animals
Male Swiss albino mice (23–30 g) and Wistar rats
(90–110 g, 200–300 g, 350–450 g) from Morini (San Polo
d’Enza, Italy) breeding farms were used. Fifteen mice
and four rats were housed per cage. The cages were
placed in the experimental room 24 h before the test for
acclimatization. The animals were kept at 23 ± 1°C with
a 12-h light/dark cycle, lights on at 7 AM, with food and
water ad libitum. All experiments were carried out ac-
cording to the guidelines of the European Community
Council for experimental animal care.
Intracerebroventricular Injection Technique
Intracerebroventricular (i.c.v.) administration was
performed under ether anesthesia using isotonic saline
as solvent, according to the method described by Haley
and McCormick [1957] for mice and which we adapted
for rats. Briefly, during anesthesia, mice and rats were
grasped firmly by the loose skin behind the head. A 0.4
mm external diameter, hypodermic needle attached to a
10 µl syringe was inserted perpendicularly through the
skull at a depth of no more than 2 mm into the brain of
the mouse and 4 mm into the brain of the rat, where 5 µl
(mice) or 10 µl (rats) were then administered. The injec-
tion site was 1.5 mm (mice) or 2.5 mm (rats) from either
side of the midline on a line drawn through to the ante-
rior base of the ears. To ascertain that the drugs were
administered exactly into the cerebral ventricle, some
mice and rats were i.c.v. injected with 5–10 µl of diluted
1:10 India ink and their brains examined macroscopically
after sectioning. The accuracy of the injection technique
was evaluated and 95% correct.
Passive-Avoidance Test
The test was performed according to the step-
through method described by Jarvik and Kopp [1967].
The apparatus consisted of a two-compartment acrylic
box with a lighted compartment connected to a darkened
one by a guillotine door. As soon as they entered the dark
compartment, mice received a punishing electrical shock
(0.5 mA, 1 sec). The latency times for entering the dark
compartment were measured in the training test and af-
ter 24 h in the retention test. For memory disruption,
animals were either exposed to a hypoxic environment
(5% O2 in water-saturated nitrogen) for 8 min up to 30
sec before passive avoidance training or injected with
amnesic drugs. Scopolamine, dicyclomine, diazepam,
benzhexol, baclofen, mecamylamine, and diphenhy-
dramine were i.p. injected immediately after the train-
ing session, whereas AF-64A was i.c.v. injected 4 h before
the training session. To improve memory, animals were
treated 20 min before the training session with SM 21,
piracetam, AF-102B, or physostigmine. The drug admin-
istration schedule was chosen on the basis of prelimi-
nary experiments in which the time-course for every
compound was determined. The maximum entry latency
allowed in the training session was 30 sec for mice and
150 sec for rats, whereas in the retention session the en-
trance latency allowed was 120 sec and 20 min, respec-
tively, for mice and rats. The memory degree of received
punishment was expressed as latencies recorded in the
retention and training sessions.
Social Learning Test
The social learning test was performed according
to Mondadori et al. [1992]. Male Wistar rats (350–450 g)
were used throughout the experiments and juvenile males
(90–110 g) were used as social stimuli. All the adult ani-
mals were housed individually and placed in the testing
room at least 24 h before the experiment. On the day
preceding the experiment, adult rats were handled to
become familiar with the operator. Juvenile rats were
housed four per cage and brought into the testing room
on the day of the experiment. Experimental sessions were
always conducted between 10 AM and 2 PM. Each mature
male rat was tested in its home cage. The first day of the
experiment, a juvenile rat was introduced into the adult
male’s cage and the time spent in social investigatory
behavior by the adult male within a 5-min fixed interval
was recorded. Social investigatory behavior was defined
as being proximally oriented to the juvenile or in direct
contact while sniffing, following, nosing, grooming, or
generally inspecting any body surface of the juvenile.
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After 24 h, either the same juvenile or an unfamiliar one
was placed again into the mature male’s cage and social
investigatory behavior was recorded in a 5-min interval.
SM 21 and piracetam were i.p. injected 20 min before
the first session of the experiment.
Spontaneous Activity Meter (Animex)
Locomotor activity in rats was quantified using an
Animex activity meter Type S (LKB, Farad, Sweden) set
to maximum sensitivity. Every movement of rats, which
were placed on the top of the Animex activity meter, pro-
duced a signal due to variation in inductance and capac-
ity of the apparatus resonance circuit. Signals were then
automatically converted to numbers. On the day of the
experiment, the rats were treated and the cage, contain-
ing three rats, was put on the measuring platform. Activ-
ity counts were made for 5 min at 15-min intervals for 45
min (total of three sessions) starting immediately after
injection of the drug. Because of the arbitrary scale
adopted to quantify movements, drug-treated rats were
always compared with saline-treated ones.
Rota-Rod Test
The apparatus consisted of a base platform and a
rotating rod of 3 cm diameter with a nonslippery surface.
This rod was placed at a height of 15 cm from the base.
The rod, 30 cm in length, was divided into five equal
sections by six disks. Thus, up to five mice were tested
simultaneously on the apparatus, with a rod-rotating
speed of 16 r.p.m. The integrity of motor coordination
was assessed on the basis of endurance time of the ani-
mals on the rotating rod. One day before the test, the
animals were trained twice. On the day of the test, only
the mice that were able to stay balanced on the rotating
rod between 70 and 120 sec (cut-off time) were selected
for testing. The performance time was measured before
and at various times after treatment.
Reagents and Compounds
The following drugs were used: SM 21 racemate
was prepared according to Gualtieri et al. [1994]; R-(+)-
SM 21 and S-(–)-SM 21 were prepared according to
Romanelli et al. [1996]; dicyclomine hydrochloride (Le
Petit, Italy); benzhexol (Cyanamid); diazepam (Valium,
Roche); mecamylamine hydrochloride; acetylethylcholine
mustard hydrochloride (RBI; Natick, MA); AF-102B (Inst.
for Neurobiol. Res., Bruxelles, Belgium); diphenhy-
dramine hydrochloride (De Angeli); scopolamine
hydrobromide; baclofen, piracetam; and physostigmine
hemisulphate (all Sigma Chemical Co., St. Louis, MO).
Drugs were dissolved in isotonic (NaCl 0.9%) sa-
line solution, with the exception of diazepam, which was
dissolved in a water and dimethyl sulphoxide (DMSO)
(3:1) vehicle immediately before use. AF-64A was pre-
pared from 10 mM acetylethylcholine mustard hydro-
chloride. It was dissolved in distilled water (pH 11.5–
11.7), and the solution was vigorously stirred for 20 min.
This solution was diluted with 0.9% NaCl and finally ti-
trated with HCl to adjust the pH to 7.3–7.4. The cere-
bral ventricles were then bilaterally infused with 2.0 nmol
of AF-64A. A total volume of 10 µl was delivered to each
side. Drug concentrations were prepared in such a way
that the necessary dose could be administered in a vol-
ume of 5 µl per mouse by i.c.v. injection and 10 ml kg–1
by i.p. injection.
Statistical Analysis
All experimental results are given as the mean ±
SEM. Analysis of variance (ANOVA), followed by Fisher’s
Protected Least Significant Difference (PLSD) procedure
for post-hoc comparison, was used to verify significance
between two means. Data were analyzed with the
StatView software for the Macintosh. P values less than
0.05 were considered significant.
RESULTS
Prevention by SM 21 of Amnesia Induced by
Antimuscarinic Drugs
Pretreatment of ACh releaser SM 21 prevented
amnesia induced by the administration of antimuscarinic
drugs in both mice and rats (Figs. 1, 2).
SM 21 dose-dependently prevented scopolamine
(1 mg kg–1 i.p.; Fig. 1A) and dicyclomine (10 mg kg–1 i.p.;
Fig. 1B) in the mouse passive avoidance test. SM 21, at
the dose of 1 and 5 mg kg–1 i.p. was completely ineffec-
tive, whereas starting from a dose of 10 mg kg–1 i.p. it
prevented antimuscarinic amnesia, reaching entrance
latency values comparable to those produced by saline-
treated mice. SM 21 was also able to prevent amnesia
induced by AF-64A (2 nmol per rat i.c.v.; Fig. 2A) and
benzhexol (10 mg kg–1 i.p.; Fig. 2B), as demonstrated by
the rat passive avoidance test. Similar to the profile ob-
served in mice, the antiamnesic effect of SM 21 reached
statistical significance at 10 mg kg–1 i.p..
SM 21 prevented antimuscarinic amnesia in both
mice and rats comparably to that exerted by the cholinest-
erase inhibitor physostigmine (0.2 mg kg–1 i.p.; Figs. 1A,B,
2B) and the M1 selective agonist AF-102B (10 mg kg
–1
i.p.; Fig. 2A). The maximum antiamnesic effect of SM 21
(20 mg kg–1 i.p.) was also equal to that produced by the
well-known nootropic drug piracetam (30 mg kg–1 i.p.)
(Fig. 1A,B). However, at active doses SM 21 did not en-
hance the entrance latency in unamnesic mice in com-
parison with the control group (Figs. 1A, 2). There were
no differences observed in the various entrance laten-
cies of every group in the training session of the passive
avoidance test (Figs. 1, 2).
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The antiamnesic effect of the two enantiomers of
SM 21, R-(+)-SM 21 and S-(–)-SM 21 was evaluated in
the mouse passive avoidance test (Fig. 3). Both enanti-
omers dose-dependently were able to prevent dicyclo-
mine-induced amnesia, even if R-(+)-SM 21 was slightly
more effective than S-(–)-SM 21. As a matter of fact, the
lowest active doses of R-(+)-SM 21 and S-(–)-SM 21
were, respectively, 10 and 20 mg kg–1 i.p. (Fig. 3). For
both enantiomers, the maximum antiamnesic effect was
reached at 20 mg kg–1 i.p., obtaining an entrance latency
value comparable to that in saline-treated mice.
Prevention by SM 21 of Amnesia Induced by
Mecamylamine, Baclofen, Diphenhydramine,
and Diazepam
The administration of SM 21 dose-dependently
antagonized the memory disruption produced by
mecamylamine (20 mg kg–1 i.p.), baclofen (2 mg kg–1 i.p.),
and diphenhydramine (20 mg kg–1 i.p.) in the mouse pas-
sive avoidance test (Fig. 4A) as well as the amnesia in-
duced by diazepam (1 mg kg–1 i.p.) in the rat passive
avoidance test (Fig. 4B).
SM 21, at 10 mg kg–1 i.p., partially prevented diaz-
epam-induced amnesia, even if statistical significance was
not reached. The dose of 20 mg kg–1 i.p. increased the
entrance latency in the retention session up to a value
comparable to that produced by control animals (Fig. 4B).
Conversely, the amnesia induced by mecamylamine,
baclofen, and diphenhydramine was prevented by lower
doses of SM 21, with 10 mg kg–1 i.p. being the first active
dose (Fig. 4A). The maximum antiamnesic effect was
reached at the dose of 20 mg kg–1 i.p.
SM 21 was active in facilitating memory similar to
Fig. 1. Dose–response curves of SM 21 in comparison with piracetam
and physostigmine on amnesia induced by scopolamine (1.5 mg kg i.p.)
(A) and dicyclomine (10 mg kg–1 i.p.) (B) in mouse passive avoidance test.
SM 21, piracetam, and physostigmine were administered 20 min before
training session, while scopolamine and dicyclomine were injected im-
mediately after. The number of mice is inside the column. *P < 0.01 in
comparison with antimuscarinic-treated mice.
Fig. 2. Prevention by SM 21 of amnesia induced by AF-64A (2 nmol icv)
in comparison with AF-102B (A) and benzhexol (10 mg kg–1 i.p.) in com-
parison with physostigmine (B) in rat passive-avoidance test. AF-64A was
injected 4 h before training session, while SM 21, AF-102B, and physostig-
mine 20 min before training session. Benzhexol was administered imme-
diately after training session. The number of rats is inside the column. *P <
0.01 in comparison with AF-64A or benzhexol-treated rats.
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Fig. 3. Dose–response curves of R-(+)- SM 21 and S-(–)- SM 21 on
amnesia induced by dicyclomine in the mouse passive avoidance test.
Both enantiomers were administered 20 min before training session while
dicyclomine was injected immediately after. Each column represents the
mean of at least 18 mice. ^P < 0.05; *P < 0.01 in comparison with
dicyclomine-treated mice.
Fig. 4. Dose–response curves of SM 21 in comparison with piracetam
on amnesia induced in mouse by mecamylamine, baclofen, and diphen-
hydramine (A) and in rat by diazepam (B) in passive avoidance test. SM
21 and piracetam were administered 20 min before training session, while
the other drugs were injected immediately after. Each column represents
the mean of at least 18 mice or 8 rats. ^ P < 0.05; *P < 0.01 in compari-
son with amnesic drug-treated animals.
the nootropic drug piracetam, regardless of the amnesic
drug used (Fig. 4A,B).
Prevention by SM 21 of the Amnesia
Induced by Hypoxia
A strong reduction in memory was obtained in mice
exposed for 8 min to 5% O2 in water-saturated nitrogen
in the passive avoidance test (Fig. 5). The intensity of
amnesia was comparable to that produced by all the am-
nesic drugs used in this study. At doses ranging between
10–30 mg kg–1 i.p., SM 21 was able to prevent the amne-
sic effect of this low oxygen concentration with an effi-
cacy comparable to that produced by piracetam, used as
a nootropic reference drug (Fig. 5). On the other hand,
SM 21 was inactive in preventing hypoxia-induced am-
nesia at lower doses (Fig. 5). At the highest active dose
SM 21 did not increase the entrance latency in
nonhypoxic mice in comparison with the saline group
(Fig. 5).
Effect of SM 21 on the rat social learning test
Adult rats were treated with SM 21 (5–10 mg kg–1
i.p.) and piracetam (30 mg kg–1 i.p.), or saline 20 min
before the first session of the test. In the adult animals
treated with SM 21 (10 mg kg–1 i.p.), the duration of ac-
tive exploration of the familiar partner at the second pair-
ing at 24 h was shortened in comparison with
saline-treated rats (Fig. 6). No curtailment was observed
if an unknown partner was presented (Fig. 6). At the dose
of 5 mg kg–1 i.p., SM 21 was ineffective. In the same
experimental conditions, a nootropic drug such as
Fig. 5. Comparison of prevention by SM 21 and by piracetam of
hypoxia-induced amnesia in the mouse passive avoidance test. Mice
were exposed to hypoxic environment (5% O2, 95% N2) for 8 min.
SM 21 and piracetam were injected 20 min before the training test.
The number of mice is inside the column. *P < 0.01 in comparison
with hypoxic-treated mice.
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piracetam reduced the time spent on exploratory behav-
ior (Fig. 6). All drugs used did not modify the duration of
active exploration in comparison with saline-treated rats
(data not shown).
Effect of Subacute Treatment With SM 21
SM 21 induced tolerance after repeated adminis-
tration. SM 21, injected twice daily for 2 weeks at a dose
at which it demonstrates full antiamnesic activity (10 mg
kg–1 i.p.), lost the ability to prevent amnesia induced by
dicyclomine (Fig. 7). By contrast, in the same experimen-
tal conditions piracetam (30 mg kg–1 i.p.), used as refer-
ence drug, still exerted antiamnesic activity (Fig. 7).
Subacute treatment with SM 21 (10 mg kg–1 i.p.) did not
evidence any loss of body weight nor the typical symp-
tomatology of withdrawal syndrome.
Effect of SM 21 on Mouse Rota-Rod Test and
Rat Animex Apparatus
It should be noted that SM 21 elicited its modu-
latory effect on cognitive processes without changing ei-
ther gross behavior or motor coordination and spontaneous
motility as revealed, respectively, by the mouse rota-rod
test (Table 1) and the rat Animex apparatus (Fig. 8). SM 21,
administered at the highest active doses, did not reduce
the endurance time on the rotating rod in comparison
with saline-treated mice (Table 1). By contrast, in the
same experimental conditions physostigmine (0.2 mg
kg–1 i.p.) reduced time spent by the animals on the rotat-
ing rod (Table 1).
The spontaneous motility of rats was unmodified
by SM 21 administration (30 mg kg–1 i.p.) as revealed by
the Animex apparatus in comparison with saline-treated
rats (Fig. 8).
DISCUSSION
The present results describe acute and subacute
effects observed with SM 21 on experimentally impaired
memory in mice and unimpaired learning in rats. SM 21
has been demonstrated to ameliorate cognitive processes
not only by preventing amnesia induced by pharmaco-
logical treatments or exposure to hypoxic environment
in the passive avoidance test, but also by producing a
procognitive activity in a social learning task.
That stimulation of the cholinergic system improves
cognitive processes has long been observed [Coyle, 1995].
On the other hand, a blockade of the cholinergic system
produces a disruption of memory functions. The admin-
istration of scopolamine, an unselective muscarinic ACh
receptor antagonist, results in impaired learning and
memory in humans [Frumier et al., 1976] and animals
[Dilts and Berry, 1967; Levin and Bowman, 1986]. Ani-
mals treated with the M1 selective antagonist pirenzepine
[Hammer et al., 1980] had impaired passive avoidance
learning in mice [Caufield, 1993] and impaired spatial
learning [Hagan et al., 1987; Hunter and Roberts, 1988],
radial arm maze performance [Sala et al., 1991], and ac-
tive avoidance acquisition [Sen and Bhattacharya, 1991]
in rats. Moreover, the M1 selective antagonists dicyclo-
mine [Nilvebrant and Sparf, 1986] and S-(–)-ET-126
[Ghelardini et al., 1996] were able to induce amnesia in a
mouse passive avoidance task [Ghelardini et al., 1997b;
Matucci et al., 1997]. Disruption of the cholinergic sys-
tem can also be obtained by the use of cholinotoxins. The
Fig. 6. Comparison of the effect of SM 21 and of piracetam in the rat
social learning test. SM 21 and piracetam were administered 20 min be-
fore the first session. The number of rats is inside the column. *P < 0.01
in comparison with saline-treated rats.
Fig. 7. Comparison of the effect of subacute treatment with SM 21 and
piracetam on dicyclomine-induced amnesia in mouse passive-avoidance
test. SM 21 (10 mg kg–1 i.p.) and piracetam (30 mg kg–1 i.p.) were in-
jected twice daily for 14 days; on the day of the experiment, both were
administered 20 min before training. The number of mice is inside the
column. *P < 0.01 in comparison with dicyclomine-treated mice.
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i.c.v. injection of the ethylcholine aziridinium ion (AF-
64A), a selective cholinotoxin, produced a deficient per-
formance in a rat passive avoidance task and a delayed
alteration task in the T-maze test [Nakahara et al., 1988].
Furthermore, the administration of nicotinic ACh recep-
tor antagonists, such as mecamylamine, produces a dose-
dependent impairment of performance in the passive
avoidance test [Elrod and Buccafusco, 1991].
It has been demonstrated by microdialysis studies
that SM 21 is able to increase ACh release from rat cere-
bral cortex [Ghelardini et al., 1997a] and hippocampus
(data not shown), two cerebral structures highly involved
in the modulation of cognitive processes [Bartus et al.,
1982]. Therefore, it is not unexpected that SM 21 is able
to prevent amnesia induced by selective and unselective
antimuscarinic drugs, by disruption of the cholinergic
neurones by the use of the antimuscarinic toxin AF-64A,
as well as by the administration of a nicotinic antagonist.
Amnesia can also be obtained by modulating neu-
rotransmitter systems different from the cholinergic.
GABA is the main inhibitory neurotransmitter in the brain
and it plays an important role in learning and memory.
The activation of GABAA receptors impairs memory per-
formance [Jerusalinsky et al., 1994] and the stimulation
TABLE I. Effect of SM 21 in Comparison With Physostigmine in the Rota-Rod Test
Endurance time on rota-rod(s)
After treatment
Before treatment 15 min 30 min 45 min
Saline ip 103.5 ± 5.6 (11) 99.7 ± 7.2 (11) 102.9 ± 5.9 (11) 96.3 ± 4.9 (11)
SM 21 30 mg kg–1 ip 98.5 ± 6.9 (10) 103.6 ± 7.7 (10) 96.2 ± 8.3 (10) 101.2 ± 8.6 (10)
Physostigmine 0.2 mg kg–1 ip 102.4 ± 4.5 (10) 65.3 ± 8.1* (10) 65.7 ± 7.3* (10) 87.4 ± 8.4* (10)
*P < 0.05 in comparison with the respective pretest value. The number of mice is shown in parentheses.
Fig. 8. Lack of effect of SM 21 on rat spontaneous motility. Vertical
lines show SEM. Each column represents the mean of eight rats.
of GABAB receptors by baclofen disrupts memory after
systemic, intraamygdala or intraseptal administration
[Swartzwelder et al., 1987; Castellano et al., 1989;
Stackman and Walsh, 1994]. Furthermore, benzodiaz-
epines have long been known to impair many forms of
learning in many species, including humans [Izquierdo
and Medina, 1991]. The antihistaminics are known to
exert a variety of effects on the central nervous system.
Central depression usually accompanies therapeutic
doses of the H1 antagonists, which appears to be related
to occupancy of cerebral H1 receptors; impairment of
cognitive functions is a common manifestation [Simons
and Simons, 1994]. Furthermore, the administration of
the cerebral H1 antagonist diphenhydramine induces
amnesia in animals also [Kamei et al., 1990; Galeotti et
al., 1998].
Cerebral hypoxia is associated with a series of mo-
lecular events which can culminate in neuronal cell death.
Exposure of cerebral structure to an environment with a
low concentration of oxygen is well known to produce am-
nesia. The administration of cholinomimetics or nootropic
drugs can prevent the amnesic effect produced by hypoxia
in both laboratory animals [DeNoble et al., 1986; Coyle,
1995] and humans [Saletu and Grünberger, 1984].
SM 21 was able to prevent amnesia induced by the
administration of baclofen, diazepam, diphenhydramine,
and hypoxia. Thus, SM 21 counteracts amnesia not only
induced by antimuscarinic drugs, but also that obtained
independently from a cholinergic blockade.
SM 21 is also endowed with antinociceptive prop-
erties [Ghelardini et al., 1997a], but the analgesia and
antiamnesia seem to be unrelated, since the first
antiamnesic dose was lower than that able to enhance
the pain threshold. A complete prevention of amnesia
was, in fact, obtained at a dose (10 mg kg–1) that was
weakly analgesic only in the hot-plate test [Ghelardini et
al., 1997a]. The time-course of the antiamnesic activity
of SM 21 was equal to that observed for its antinociceptive
action, reaching its maximum between 15–30 min after
injection (data not shown). Therefore, in the learning and
memory experiments SM 21 was administered 20 min
before the training session.
In the passive avoidance test, an improvement of
cognition in animals which have no memory impairment
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is difficult to demonstrate. As a matter of fact, not only
SM 21 but also well-known nootropic drugs, such as
piracetam and aniracetam, or cholinomimetics, such as
physostigmine and oxotremorine, do not show any
memory facilitation in unamnesic animals [Gouliaev and
Senning, 1994; Coyle, 1995]. However, a procognitive
activity of SM 21 was unmasked by using a social learn-
ing test in which adult rats with unimpaired memory were
used. SM 21, as well as piracetam, improved cognitive
performance by prolonging the time spent by rats delet-
ing mnemonic information.
In the first session, the latency to enter the dark
compartment of the light–dark box in the passive avoid-
ance test, as well as the duration of exploratory activity
in the social learning test, were not modified by the ad-
ministration of SM 21. This observation was confirmed
by evaluation of the motor coordination in mice and spon-
taneous motility in rats. SM 21, at the highest doses used,
did not impair motor coordination as revealed by the rota-
rod test or modify spontaneous motility as indicated by
the Animex apparatus. Furthermore, SM 21 did not elicit
the typical cholinergic symptoms (tremors, sialorrhea,
diarrhea, rhinorrhea, lacrimation, etc.) produced by in-
jection of direct postsynaptic muscarinic agonists. In
other words, SM 21 is able to counteract amnesia and to
exert a procognitive activity in a more physiological man-
ner than the cholinergic activators, such as physostigmine
or AF-102B, used as reference drugs.
In conclusion, these results indicate the ability of
SM 21 to modulate memory processes. On these bases,
SM 21 could be considered a new potential antiamnesic
drug useful in the treatment of cognitive disorders.
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